NCT03541655View on ClinicalTrials.gov

Safety and Activity of F14 for Management of Pain Following Total Knee Replacement

PHASE2CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

May 4, 2018

Primary Completion Date

June 20, 2019

Study Completion Date

March 30, 2020

Conditions
Total Knee ReplacementPostoperative Pain
Interventions
DRUG

Bupivacaine HCl

0.25% Bupivacaine HCl

DRUG

F14 (celecoxib)

Celecoxib in novel drug delivery system (BEPO™)

Trial Locations (3)

45417

Midwest Clinical Research Center, Dayton

78229

Endeavor Clinical Trials, San Antonio

80401

Panorama Orthopedics & Spine Center, Denver

Sponsors
All Listed Sponsors
lead

Arthritis Innovation Corporation

INDUSTRY

NCT03541655 - Safety and Activity of F14 for Management of Pain Following Total Knee Replacement | Biotech Hunter | Biotech Hunter